Christophe Bailleul - Mauna Kea Insider

MKEA -- France Stock  

EUR 2.94  0.16  5.16%

Mr. Christophe Bailleul is VicePresident Clinical Affairs, Health Economics and Market Access of Mauna Kea Technologies SAS. He joined Mauna Kea Technologies in 2015 and brings a wealth of clinical knowledge to the company with more than 25 years of international experience in the biotech and medical device sectors. He started his career in a French biotech startup affiliate of the National Blood Transfusion Foundation in the late 80s. He then spent 5 years in Germany as a research and quality assurance manager in a young CRO, PRA International. He also worked in the clinical development field at Ela Medical, which is part of Sorin Group. From 2002 on he was based in Belgium as the VP of Clinical Affairs and Health Economics of the International Division at St. Jude Medical. He holds multiple academic degrees including, an engineering degree from the Universite de technologie de Compiegne in France, an MSc in blood transfusion and immunology, a PhD in immunobiotechnologies and an MBA from ESSEC in Paris, France.
  President Since 2015  MBA    
33 1 48 24 03 45

Management Efficiency

The company has return on total asset (ROA) of (25.43) % which means that it has lost $25.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (73.44) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 6.95 M in total debt with debt to equity ratio (D/E) of 41.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mauna Kea Technologies SA has Current Ratio of 5.67 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 12 records


HansJoachim KrebsCellnovo Limited
Philippe GarciaAmplitude Surgical SA
Jamie MilasEOS imaging SA
Bruno JugnetAmplitude Surgical SA
Bradley GarrettSuperSonic Imagine SA
JeanChristophe VialAmplitude Surgical SA
Eric MaulaveEOS imaging SA
Steve BubrickCellnovo Limited
Jerome WindsorMedian Technologies SA
Laurent GeaisAmplitude Surgical SA
Philippe LutmanSuperSonic Imagine SA
Reman McDonaghCellnovo Limited

Entity Summary

Mauna Kea Technologies SA, a medical device company, develops and sells endomicroscopy and optical biopsy for the diagnosis and treatment of cancer and other diseases. The company was founded in 2000 and is headquartered in Paris, France. Mauna Kea operates under Medical Devices classification in France and traded on Paris Stock Exchange. It employs 90 people.Mauna Kea Technologies SA (MKEA) is traded on Paris Stock Exchange in France. It is located in 9, rue d'Enghien and employs 90 people.

Mauna Kea Technologies Leadership Team

Olivier Regnard, Deputy CEO, CFO
Bertrand Talhouet, Representative of Creadev on the Board of Directors
Eric Cohen, CFO and VP of Fin.
Gilles Brisson, Chairman, Independent Director
Alexandre Loiseau, CEO, Director
Guillaume Bailliard, President for North America
Christopher McFadden, Director
Francois Lacombe, Chief Scientific Officer
Christopher Tihansky, Chief Devel. Officer and President of North America
JeanLuc Boulnois, Director
Bruno Villaret, Vice President of International Sales
Joseph DeVivo, Non-Executive Independent Director
Christophe Bailleul, Vice-President Clinical Affairs, Health Economics and Market Access
Agnes Rouffiac, Director of Human Resources
Veronique Dentan, Director of Operations
Sebastien Cadet, Global Director of Marketing and OEM Leader
Sacha Loiseau, Founder, CEO and Director
Molly ONeill, Director
Pierre Forest, COO
John Soto, COO
Marie Meynadier, Director

Stock Performance Indicators

Current Sentiment - MKEA

Mauna Kea Technologies Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Mauna Kea Technologies SA. What is your trading attitude regarding investing in Mauna Kea Technologies SA? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.